WallStreetZenWallStreetZen

NYSE: NVO
Novo Nordisk A S Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Novo Nordisk (Ozempic) earnings were $15.9B for the trailing 12 months ending Mar 31, 2025, with 18.1% growth year over year. The latest NVO earnings report on Mar 31, 2025 announced Q1 2025 earnings of $4.2B, up 7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NVO reported annual earnings of $14.1B, with 13.6% growth.

NVO past earnings growth

How has NVO's earnings growth performed historically?

Company
18.06%
Industry
11.53%
Market
34%
NVO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
NVO's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
NVO's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

NVO earnings history

Current Revenue
$44.0B
Current Earnings
$15.2B
Current Profit Margin
34.5%
NVO's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

NVO Return on Equity

Current Company
81.2%
Current Industry
-60.2%
Current Market
31.5%
NVO's Return on Equity (81.2%)... subscribe to Premium to read more.
High Return on Equity Performance

NVO undefined

Current Company
24.3%
Current Industry
-2.5%
NVO is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when NVO announces earnings.

NVO undefined

Current Company
52.29%
Current Industry
5.8%
NVO's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NVO vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
NVO$23.12B$15.87B+22.09%$3.57
VRTX-$74.90M-$988.90MN/A-$3.82
REGN$5.53B$4.50B+14.92%$41.77
ALNY-$164.54M-$269.70MN/A-$2.09
ARGX$114.32M$905.48MN/A$15.13
View Top Biotech Stocks

Novo Nordisk (Ozempic) Earnings Reports & History FAQ

What were Novo Nordisk (Ozempic)'s earnings last quarter?

On NVO's earnings call on Invalid Date, Novo Nordisk (Ozempic) (NYSE: NVO) reported Q1 2025 earnings per share (EPS) of $0.95, up 15.03% year over year. Total NVO earnings for the quarter were $4.21 billion. In the same quarter last year, Novo Nordisk (Ozempic)'s earnings per share (EPS) was $0.83.

If you're new to stock investing, here's how to buy Novo Nordisk (Ozempic) stock.

Is Novo Nordisk (Ozempic) profitable or losing money?

As of the last Novo Nordisk (Ozempic) earnings report, Novo Nordisk (Ozempic) is currently profitable. Novo Nordisk (Ozempic)'s net profit (also called net income) for the twelve months ending Mar 31, 2025 was $15.18 billion, a 17.52% increase year over year.

What was NVO's earnings growth in the past year?

As of Novo Nordisk (Ozempic)'s earnings date in Invalid Date, Novo Nordisk (Ozempic)'s earnings has grown 18.06% year over year. This is 6.53 percentage points higher than the US Biotechnology industry earnings growth rate of 11.53%. NVO earnings in the past year totalled $15.87 billion.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.